

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**康臣藥業集團有限公司**  
CONSUN PHARMACEUTICAL GROUP LIMITED

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1681)**

## **Voluntary Announcement**

### **Notice of Approval for Clinical Trial for SK-09 Tablet**

This announcement is made by Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with the updates on the development of the business of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has received the “Notice of Approval for Clinical Trial of Drug\* (《藥物臨床試驗批准通知書》)” issued by the National Medical Products Administration in relation to the SK-09 Tablet. The relevant information is hereby announced as follows:

Drug name	: SK-09 Tablet
Application	: Registration of clinical trial of pharmaceutical product
Acceptance number	: CXHL2500149 CXHL2500150
Applicant	: Guangzhou Consun Pharmaceutical Company Limited (廣州康臣藥業有限公司) (a wholly-owned subsidiary of the Company)
Review conclusion	: In accordance with the Drug Administration Law of the People’s Republic of China* (《中華人民共和國藥品管理法》) and the relevant regulations, upon review, the application for clinical trial of SK-09 Tablet, which was accepted for processing on 5 February 2025, meets the relevant requirements for drug registration and it is approved that the clinical trial of this product can be commenced.
Indication for the application	: Treatment of podocyte injury-related renal diseases (DN, FSGS and MCD etc.)

## **About SK-09 Tablet**

SK-09 Tablet is a Category 1 of Chemical Drugs.

Podocyte injury-related renal disease is a kind of kidney disease characterized by glomerular podocyte injury as the primary pathological feature. This kind of disease includes diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS) and minimal change diseases (MCD). Patients often failed to receive timely and effective treatment and ultimately progressed to end-stage renal disease (ESRD), hence imposing a significant burden on the patients, their families and the social healthcare system. Currently, there are no targeted therapies available for podocyte protection. The clinical development of SK-09 Tablet is expected to provide a more precise and effective new treatment option for patients with kidney disease.

**As there are significant risks and uncertainties in the process of research, development and commercialization of pharmaceutical products, shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. The Company will actively pursue the above-mentioned research and development projects and will comply with its obligations to disclose information on the subsequent progress of the projects in a timely manner in strict accordance with the relevant regulations.**

By Order of the Board  
**Consun Pharmaceutical Group Limited**  
**AN Meng**  
*Chairman*

Hong Kong, 25 April 2025

*As at the date of this announcement, the Board comprises Mr. An Meng, Professor Zhu Quan and Mr. Young Yuk Chuen David as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi, Professor Li Yikai, Mr. Li Zhuoguang and Mr. Duan Weiwu as independent non-executive Directors.*

\* *for identification only*